Immorta Bio will present positive results of lung, breast,
pancreatic, and brain cancer experiments
MIAMI, March 5,
2025 /PRNewswire/ -- Immorta Bio Inc., a leader
in longevity-focused biotechnologies, announced today acceptance of
its poster presentation at the upcoming Society for Immunotherapy
of Cancer (SITC) Spring Scientific, Cellular Therapy for Solid
Tumors in San Diego, CA, on March
12-13, 2025.
The company will present molecular and cellular mechanisms by
which its First-In-Class Senolytic Immunotherapy specifically kills
senescent cells associated with cancer initiation, progression, and
protection.
"We plan to present data demonstrating regression of cancers in
animal models of glioma, lung, breast, and pancreatic cancers using
our SenoVax approach," said Dr. Thomas
Ichim, President and Chief Scientific Officer of Immorta
Bio. "SenoVax is an autologous senescent cell pulsed dendritic cell
product for which we plan to start clinical trials for lung cancer
shortly.
The poster is a result of Immorta Bio collaboration with
esteemed institutions, including the University of California San Diego, George Washington University, Cedars-Sinai, and
Calidi Biosciences.
"The Society for Immunotherapy of Cancer is the world's leading
organization dedicated to the advancement of cancer
immunotherapy. For us to be selected to present in front of
such a distinguished audience is significant accomplishment and
indicates acceptance of our "paradigm-shifting" approach in that we
kill cancer by targeting the senescent cells surrounding it," said
Dr. Boris Reznik, Chairman and CEO
of Immorta Bio. "Based upon our preclinical data we anticipate to
also see SenoVax™ to reduce systemic senescent cells load resulting
in associated "antiaging" effects in treated patients."
About Immorta Bio
Immorta Bio Inc., a scientific longevity company focused on
"Treating Diseases of Aging and Treating Aging as Disease™,"
leverages anti-aging technologies to tackle pressing medical
challenges, from advanced cancers to other age-related conditions.
To learn more about Immorta Bio' research initiatives,
visit immortabio.com, LinkedIn and X.
Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/senovax-first-in-class-senolytic-product-to-be-presented-at-society-for-immunotherapy-of-cancer-symposium-302393115.html
SOURCE Immorta Bio Inc
